Literature DB >> 16676254

[Surgical coverage technics of pressure sores and their outcomes].

Ufuk Bilkay1, Evren Helvaci, Cenk Tokat, Cüneyt Ozek, Yalçin Akin.   

Abstract

BACKGROUND: We reviewed the outcome of 66 patients with 100 pressure sores between 1984 and 2002.
METHODS: In the current study, 100 pressure sores in 66 patients (45 male, 21 female; mean age 39.4; range 13 to 80 years) who underwent surgical repair of pressure sores reconstructed using myocutaneous or fasciocutaneous flaps, skin grafts, excision and closure.
RESULTS: The risk factors for pressure sores included acute trauma-induced spinal cord injury in 40 (61%) patients with paraplegia and in 5 (7%) patients with quadriplegia; congenital spina bifida and multiple sclerosis in 7 (11%) patients and prolonged immobilization in 14 (21 patients) patients. We achieved an overall pressure sore recurrence rate of 22% and overall patient recurrence of 24% in a-3-year follow-up. The recurrence rates according to anatomic sites; 23% (10 of 43) for the ischial pressure sore, sacral 21% (8 of 37), and trochanteric 20% (4 of 20). Fasciocutaneous and myocutaneous flap reconstructions were the most durable, as they were associated with 17% (6 of 34) and 12% recurrence rates (5 of 39).
CONCLUSION: To reduce the recurrence rates the authors advocate the use of myocutaneous and fasciocutaneous flaps instead of skin grafts or direct closure for the coverage of pressure sores.

Entities:  

Mesh:

Year:  2006        PMID: 16676254

Source DB:  PubMed          Journal:  Ulus Travma Acil Cerrahi Derg


  2 in total

1.  Surgical management of pressure ulcers during inpatient neurologic rehabilitation: outcomes for patients with spinal cord disease.

Authors:  Abhishek Srivastava; Anupam Gupta; Arun B Taly; Thyloth Murali
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

2.  The operative treatment of pressure sores in the pelvic region: A 10-year period overview.

Authors:  János Jósvay; András Klauber; Béla Both; Péter B Kelemen; Zsombor Z Varga; Pál Cs Pesthy
Journal:  J Spinal Cord Med       Date:  2014-10-09       Impact factor: 1.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.